The researchers found that the combination of the drugs silybin and carvedilol works much better against liver fibrosis than either drug alone. This pair focuses on the root causes of liver scarring. In experimental models, it significantly reduces collagen production and liver damage. Both drugs are already approved and commonly prescribed. This discovery is promising for a rapid transition into clinical practice. Previous treatments for liver fibrosis have failed, where this combination can succeed.